Skip to Content
Merck
All Photos(1)

Documents

Safety Information

R8005

SAFC

RPMI-1640 Medium

Hybri-Max™, Modified, with L-glutamine, 4500 mg/L glucose and 15mM HEPES, without sodium bicarbonate, powder, suitable for hybridoma

Pharma Manufacturing

Synonym(s):

RPMI 1640 Culture Medium

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

MDL number:
MFCD00217820
UNSPSC Code:
12352207
NACRES:
NA.75

Quality Level

500

form

powder

technique(s)

cell culture | hybridoma: suitable

impurities

endotoxin

components

phenol red: 0.0053 g/L
L-glutamine: 0.3 g/L
HEPES: 3.5745 g/L
NaHCO3: no
glucose: 4.5 g/L (Dextro)

shipped in

ambient

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

RPMI 1640 Medium was developed at Roswell Park Memorial Institute in 1966 by Moore and his co-workers. A modification of McCoy′s 5A Medium, it was formulated to support lymphoblastoid cells in suspension culture, but it has since been shown to support a wide variety of cells that are anchorage-dependent. Originally intended to be used with a serum supplement, RPMI 1640 has been shown to support several cell lines in the absence of serum. It has also been widely used in fusion protocols and in the growth of hybrid cells. This medium is suitable for culturing human normal and neoplastic leukocytes.

Quantity

Formulated to contain 16.4 grams of powder per liter of medium.

Reconstitution

Supplement with 2.0 g/L sodium bicarbonate.

Legal Information

Hybri-Max is a trademark of Sigma-Aldrich Co. LLC

also commonly purchased with this product

Product No.
Description
Pricing

supplement

Product No.
Description
Pricing

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

R8005-50K:
R8005-25KG:
R8005-PROC:
R8005-25K:
R8005-VAR:
R8005-BULK:
R8005-2X5L:
R8005-50KG:
R8005-BIBC:
R8005-50L:
R8005-1L:
R8005-10X1L:
R8005LF1-BIBC:
R8005-10L:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ryoichi Arita et al.
Diabetes, 58(1), 215-226 (2008-10-09)
Leukocyte adhesion in retinal microvasuculature substantially contributes to diabetic retinopathy. Involvement of the Rho/Rho kinase (ROCK) pathway in diabetic microvasculopathy and therapeutic potential of fasudil, a selective ROCK inhibitor, are investigated. Localization of RhoA/ROCK and Rho activity were examined in
Fhernanda R Smiderle et al.
BMC complementary and alternative medicine, 11, 58-58 (2011-07-27)
Mushroom polysaccharides have traditionally been used for the prevention and treatment of a multitude of disorders like infectious illnesses, cancers and various autoimmune diseases. Crude mushroom extracts have been tested without detailed chemical analyses of its polysaccharide content. For the
Tamara Veiga-Parga et al.
PLoS pathogens, 7(12), e1002427-e1002427 (2011-12-17)
Ocular herpes simplex virus infection can cause a blinding CD4⁺ T cell orchestrated immuno-inflammatory lesion in the cornea called Stromal Keratitis (SK). A key to controlling the severity of SK lesions is to suppress the activity of T cells that
Yoichi Matsuo et al.
International journal of cancer, 124(4), 853-861 (2008-11-28)
CXC-chemokines are involved in the chemotaxis of neutrophils, lymphocytes and monocytes. However, role of these chemokines in tumorigenesis, especially with regard to interaction between tumor and its microenvironment, has not been clearly elucidated. The purpose of this study was to
Oleh Taratula et al.
Journal of controlled release : official journal of the Controlled Release Society, 140(3), 284-293 (2009-07-02)
Low penetration ability of Small Interfering RNA (siRNA) through the cellular plasma membrane combined with its limited stability in blood, limits the effectiveness of the systemic delivery of siRNA. In order to overcome such difficulties, we constructed a nanocarrier-based delivery
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service